Anne Hersey ChEMBL Group, EMBL-EBI ChEMBL – A Database of Bioactive Drug-like Small Molecules.

Slides:



Advertisements
Similar presentations
Dr Claes Wilhelmsson Executive Director Research & Development Innovation and the life sciences.
Advertisements

The Drug Discovery Process
Challenges in new drug discovery in South Asia
Services | Research | Training | Industry Small Molecules Resources at the EBI Dr. Louisa Bellis Chemical Content Curator, ChEMBL Group EMBL-EBI, UK Bioinformatics.
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
MitoInteractome : Mitochondrial Protein Interactome Database Rohit Reja Korean Bioinformation Center, Daejeon, Korea.
Lipinski’s rule of five
EBI is an Outstation of the European Molecular Biology Laboratory. Overview of ChEMBL Database Gareth Owen, ChEBI group, EMBL-EBI Northwestern University.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
Computational Molecular Biology (Spring’03) Chitta Baral Professor of Computer Science & Engg.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Why microarrays in a bioinformatics class? Design of chips Quantitation of signals Integration of the data Extraction of groups of genes with linked expression.
Stefan Franzén Introduction to clinical trials.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
Drug-Like Properties: Optimizing Pharmacokinetics and Safety During Drug Discovery Li Di and Edward H. Kerns ACS Short Course.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Private to Public Domain Transfer
Drug discovery and development
Webinar: Wed 13 th May 2015 UniChem Jon Chambers and Anne Hersey, ChEMBL group, The European Bioinformatics Institute, part of the European Molecular Biology.
Obtaining and Negotiatiing a Position in Industry/Biotech Roy G. Smith Ph.D. Director, Huffington Center on Aging Professor, Department of Molecular and.
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Knowledgebase Creation & Systems Biology: A new prospect in discovery informatics S.Shriram, Siri Technologies (Cytogenomics), Bangalore S.Shriram, Siri.
Rational Drug Design Soma Mandal, Mee'nal Moudgil, Sanat K. Mandal.
Stefan Franzén Introduction to clinical trials.
1 Discovering new drugs in Africa Defeating Malaria Together Kelly Chibale PhD FRSSAf University of Cape Town.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
CS 790 – Bioinformatics Introduction and overview.
Exploratory IND Studies
CZ3253: Computer Aided Drug design Lecture 3: Drug and Cheminformatics Databases Prof. Chen Yu Zong Tel:
Concepts and Applications of Pharmacokinetics
Drug Discovery Process Massimiliano Beltramo, PhD.
ChEMBL– Open Access Database For Drug Discovery By – Udghosh Singh M.S.(Pharm), 3 rd Sem Pharmacoinformatics.
Developing medicines for the future and why it is challenging Angela Milne.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Proteomics Session 1 Introduction. Some basic concepts in biology and biochemistry.
Bioinformatics and Computational Biology
A database of biological pathways and processes (borrowed from a presentation created by Steve Jupe)
“Journey of a Drug” From Test Tube TO Prescribing Physician.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
PubChem: An Open Repository for Chemical Structure and Biological Activity Information Steve Bryant The NIH Biowulf Cluster: 10 Years of Scientific Supercomputing.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Shows tendency for mergers. These big companies may be shrinking – much research is now outsourced to low cost countries like Latvia, India, China and.
OncoTrack Bioinformatics Workshop Max Planck Institute for Molecular Genetics, Berlin Wednesday 6 th November 2013 TimeSubject 13:30-15:00 Introduction.
Drug Discovery & Development
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Pharmaceutical Approaches to Antiviral Drug Discovery
Molecular Modeling in Drug Discovery: an Overview
Physiochemical properties of drugs Some background to the Sirius T3.
Modern Drug Discovery for Dummies KSEA-NE Symposium March 1, 2008 Taeyoung Yoon.
Structural Bioinformatics in Drug Discovery Melissa Passino.
1/18 GLIDA: GPCR-ligand database for chemical genomic drug discovery Reporter: Yu Lun Kuo Date: November 28,
Cheminformatics and Metabolism Team The EBI Enzyme Portal.
Introduction to PubChem BioAssay
Drug UCIBIO Maria João Ramos
Drug Discovery &Development
Medicinal Chemistry III
Intersecting different databases to define the inner and outer limits of the data-supported druggable proteome
Drug Discovery – Setting the Scene
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Biotechnology Objectives: At the end of this lecture we will be able to identify and describe the uses of biotechnology in society.
ADME/Tox PredictionTox Prediction. The characterization of Absorption, Distribution, Metabolism, and Excretion (also known as ADME) and Toxicity are essential.
An Introduction to Medicinal Chemistry 3/e
Structural Bioinformatics in Drug Discovery
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
PREDICT.
Drug Design and Drug Discovery
Volume 21, Issue 9, Pages (September 2014)
Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept -A Panel Discussion Stanley C. McDermott, PharmD, MS,
Presentation transcript:

Anne Hersey ChEMBL Group, EMBL-EBI ChEMBL – A Database of Bioactive Drug-like Small Molecules

Outline ChEMBL Bioactivity Database for Drug Discovery UniChem Unified Chemical Structure Cross-referencing System 2

What is ChEMBL Open access database for drug discovery Freely available (searchable and downloadable) Content: Bioactivity data manually extracted from the primary medicinal chemistry literature from journals such as J. Med. Chem. Subset of data from PubChem Deposited data e.g. neglected disease screening, GSK kinase set Bioactivity data is associated with a biological target and a chemical structure Compounds are stored in a structure searchable format Protein targets are linked to protein sequences in UniProt Updated regularly with new data Secure searching ( ) 3

ChEMBL Content 4

Data Example CC chemokine receptor-3 (CCR3) antagonists J.R. Pruitt et al. Bioorganic & Medicinal Chemistry Letters 17 (2007) 2992–2997 5

View of data in ChEMBL 6 Compound details Target detailsActivity detailsAssay details Reference

ChEMBL Targets: ProteinProtein complex Protein family Nucleic Acid e.g., Nicotinic acetylcholine receptor e.g., Muscarinic receptors Cell Line TissueSub-cellular Fraction Organism e.g., DNA e.g., Mitochondria e.g., Nervous e.g., HEK293 cellse.g., Drosophila e.g., PDE5 7

Functional: 8 Target association Disease association Whole organism assays (e.g., anti-infectives/parasitics) Disease-derived cell-line (e.g., human ovarian cancer cell line cytotoxicity) Tissue or cell-based disease model (e.g., glucose uptake by adipocytes) Tissue or cell-based assay for target effect (e.g., contraction of guinea-pig ileum) Cell-based assay over-expressing target (e.g., GPCR calcium mobilisation) ChEMBL Assays – Binding, Functional, ADMET Binding: Assays which directly measure the binding of a compound to a particular target E.g., competition binding assays with a radioligand

ADMET: ADME Absorption, Distribution, Metabolism, Excretion 9 Toxicity Hepatotoxicity, nephrotoxicity, cytotoxicity, cardiotoxicity (hERG, QT prolongation),

Accessing ChEMBL Data 10

Integration with other Public Resources 11 Links to other databases: compounds proteins genes domains ChEMBL NTD GPCR SARfar i Kinase SARfar i ADME SARfari PubChem (subset) Deposited data

Information on a Target – Target Report Card 12

Compound Search – Compound Report Card 13

Target Discovery Lead Discovery Lead Optimisation Preclinical Development Phase 1 Phase 2 Phase 3 Launch Target identification Microarray profiling Target validation Assay development Biochemistry Clinical/Animal disease models High-throughput Screening (HTS) Fragment-based screening Focused libraries Screening collection Medicinal Chemistry Structure-based drug design Selectivity screens ADMET screens Cellular/Animal disease models Pharmacokinetics Toxicology In vivo safety pharmacology Formulation Dose prediction PK tolerability Efficacy Safety & Efficacy Indication Discovery & expansion DiscoveryDevelopment Use Clinical Trials Compounds from Med. Chem. Projects CandidatesDrugs Discovery to Development to Market 14

15 Drugs and Clinical Candidates Also added and annotated: FDA approved drugs from orange book (~1800) All compounds with USAN/INN names (~10,000)

16 DailyMed Data - Work in Progress

Probing the Link between Potency, ADMET and Physicochemical Parameters 17 Analysis of ChEMBL data shows: Average dose for oral drugs is not <10mg/day Average potency for oral drugs is not 1nM Dose is only weakly correlated with potency ~50% of drugs bind to >1 target with <1uM potency 34mg/day30nM Number of targets with <1uM potency P Gleeson et al, NRDD (2011),10 p

UniChem 18 Unified Chemical Structure Cross-referencing System

Multiple EBI Resources hold Compound Structure Data EU_OPENSCREEN etc ? - Maintaining links between DBs is a manual/time consuming for each source. - Business rules for constructing identifiers not consistent – users confused. ‘CHEMBL221572’ ‘10003’ ‘RIO’ ‘EU-?????’ ‘RIBOSTAMYCIN’ ??’ 19

All EBI DBs share the maintenance overhead of creating links to each other All EBI DBs share the benefits of maintained links to external resources The UniChem mapping service is freely available to all external users etc EU_OPENSCREEN Links to EBI and external sources are shared 20

UniChem Rapid cross-referencing of chemical structures and their identifiers between databases InChi based ‘Unified Chemical Identifier' system J Chambers et al., J Chem Inf (2013), 5(3) InChI 1S/C9H14N2/c1-8(11(2)3) /h4-8H,1-3H3/t8-/m0/s1 Connectivity Stereochemistry Molecular Formula InChIKey MSDVRBYHBSTAOM-QMMMGPOBSA-N Hydrogens 21

UniChem - Sources 22

UniChem – InChi or Identifier Searching 23

UniChem – InChi or Identifier Searching 24 InChi/InChiKey Searching Identifier Searching

UniChem – Source Mapping 25

UniChem and ChEMBL Compound cross references dynamically called from report card page KTUFNOKKBVMGRW-UHFFFAOYSA-N 26

Useful Information 27 ChEMBL Blog: For ChEMBL news and data releases subscribe to: ChEMBL Paper (NAR 2011) ChEMBL Website

Acknowledgements John Overington Anna Gaulton Mark Davies Patricia Bento Jon Chambers Francis Atkinson Louisa Bellis 28 Yvonne Light George Papadatos Shaun McGlinchey Nathan Dedman Michal Nowotka Ruth Akhtar